The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey.
No Thumbnail Available
Date
2014-08-24
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
We investigated the use of Alzheimer s disease AD biomarkers in European Alzheimer s Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment MCI We surveyed availability frequency of use and confidence in diagnostic usefulness of markers of brain amyloidosis amyloid positron emission tomography PET cerebrospinal fluid CSF A 42 and neurodegeneration medial temporal atrophy MTA on MR fluorodeoxyglucose positron emission tomography FDG PET CSF tau The most frequently used biomarker is visually rated MTA 75 of the 37 responders reported using it always frequently followed by CSF markers 22 FDG PET 16 and amyloid PET 3 Only 45 of responders perceive MTA as contributing to diagnostic confidence where the contribution was rated as moderate Seventy nine percent of responders felt very extremely comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal P Under 02 versus any individual biomarker Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature